Drug Type Biosimilar, Monoclonal antibody |
Synonyms Risankizumab-RZAA Biosimilar (Prestige BioPharma Ltd.), IDC 2502, IDC-2502 + [1] |
Target |
Action inhibitors |
Mechanism IL-23p19 inhibitors(Interleukin-23 subunit p19 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D11052 | Risankizumab Biosimilar (Prestige BioPharma) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Immune System Diseases | Discovery | Singapore | 01 Jul 2025 |






